PublicationsEpithelial-to-mesenchymal transition as a robust biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma

Epithelial-to-mesenchymal transition as a robust biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma